Hepatic Impairment Study for Lorlatinib in Cancer Patients
Status:
Recruiting
Trial end date:
2023-04-26
Target enrollment:
Participant gender:
Summary
This is a phase 1 study in advanced cancer patients with varied hepatic fucntions to evaluate
the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and
provide dose recommendation for patients with hepatic impairment if possible.